Iph4102-201
WebIPH4102 alleen of in combinatie met chemotherapie bij patiënten met gevorderd T-cellymfoom TELLOMAK: T-cellymfoom Anti-KIR3DL2-therapie. Een open label, … Web3 dec. 2024 · innate pharma announces updated results that support advancement of iph4102 in refractory sÉzary syndrome at the american society of hematology 2024 annual meeting differentiating... march 26, 2024
Iph4102-201
Did you know?
Web• Initiation of IPH4102 , an international, openTELLOMAK -label, multicohort Phase II - study evaluating the efficacy and safety of IPH4102 in patient populations larger expressing KIR3DL2, including peripheral T cell lymphoma (PTCL). TELLOMAK is planned to recruit up to 250 patients, with IPH4102 evaluated as a single agent in WebAn open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma. 2024-003969-33 Databank klinische proeven
WebTELLOMAK - IPH4102-201 T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of … Web本发明涉及与分子支架共价结合的多肽，其使得两个或更多个肽环在支架的连接点之间相对。特别地，本发明描述了作为结合 ...
WebInnate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the design of the “TELLOMAK” Phase II trial and new preclinical data supporting the potential of IPH4102 in peripheral T-cell lymphoma (“PTCL”) as well as Adult T-cell leukemia/lymphoma (“ATLL”) will be presented at the International Conference on … WebIPH4102-201: National Competent Authority: Italy - Italian Medicines Agency: Clinical Trial Type: EEA CTA: Trial Status: Ongoing: Date on which this record was first entered in the …
Web12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der Weyden , Martine Bagot , Paul Neeson , Phil K. Darcy & H. Miles Prince
WebClinical Trial Name: IPH4102-201 / TELLOMAK study Clinical Trial Description: The trial is an open label, multi-cohort and multi-center phase II. It is designed to include a total of 3 … lux wall thermometerWeb15 jun. 2024 · IPH4102 is Innate Pharma’s wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. 25 patients, with a median age of 71 years old and a median number of four prior systemic treatments, were evaluable for safety (10 dose levels: 0.0001 to 10 mg/kg). lux wall thermostatWeb25 jun. 2024 · IPH4102 is a humanised, first-in-class, monoclonal antibody that targets KIR3DL2, a cell surface protein widely expressed in cutaneous T-cell lymphoma, and … luxwall ann arbor miWebProtocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma Zhou, A. Medpace Clinical Research LLC, Innate Pharma SA 4/12/22 → 4/12/25 Project: Research project lux wand too tomicWebBackground: IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its … luxvil hearing aidsWeb26 okt. 2016 · IPH4102 is Innate Pharma's wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. luxwares torun plastikWeb15 jun. 2024 · About IPH4102: IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T... lux wall decor